A Study to Investigate the Safety of AZD6750
Phase 1/2
60
about 4.2 years
18+
6 sites in MI, MO, PA +2
About this study
Researchers are testing the safety of a treatment called AZD6750 in adults with certain advanced or metastatic solid tumors. The trial will last for about 1 year and involve approximately 60 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AZD6750
- 2.Take rilvegostomig
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Secondary: PK Area Under Curve (AUC)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Clearance- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Half-life- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Maximum plasma concentration (Cmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Minimum observed concentration (Cmin)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), PK Time to maximum plasma concentration (tmax)- Part 1A and Part 2A (dose escalation) and Part 2B (dose expansion), Pharmacodynamic- Part 1A & Part 2A (dose escalation) and Part B (dose expansion)
Oncology